Ajay Dar, MD
Medical Oncology · Leesburg, VANPI 1215905286
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,482 and has fallen 76.9% since, to $343 in 2025.
Across 132 payments — averaging $25.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$540
- AstraZeneca$442
- Novartis$441
- Pfizer$162
- Merck$148
- Eisai Inc.$142
- plus $2K from 27 others
Across 216 payments — averaging $3370.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$655K
- Janssen Research & Development, LLC$55K
- Incyte Corporation$13K
- AstraZeneca$5K
What the payments were for
- Food & beverage$3,28296%
- Education$1224%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 19 | $540 |
| AstraZeneca(2 entities) | 18 | $442 |
| Novartis | 20 | $441 |
| Pfizer | 8 | $162 |
| Merck | 7 | $148 |
| Eisai Inc. | 6 | $142 |
| Intuitive Surgical | 1 | $116 |
| Daiichi Sankyo Inc. | 5 | $114 |
| Olympus America Inc. | 1 | $113 |
| Astellas Pharma US Inc | 4 | $98 |
| Genentech USA, Inc. | 4 | $98 |
| Tempus AI, Inc | 2 | $92 |
| GSK | 4 | $89 |
| Gilead(2 entities) | 4 | $80 |
| Amgen | 3 | $74 |
| Incyte Corporation | 3 | $71 |
| Sanofi | 2 | $69 |
| Lilly USA, LLC | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| AbbVie | 1 | $52 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $51 |
| Tersera Therapeutics LLC | 2 | $43 |
| Myriad Genetic Laboratories, Inc. | 1 | $34 |
| Seagen Inc. | 1 | $33 |
| Mirati Therapeutics, Inc. | 1 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| Genmab U.S., Inc. | 1 | $28 |
| Blueprint Medicines Corporation | 1 | $22 |
| Beigene USA, Inc. | 1 | $21 |
| Novocure Inc. | 1 | $21 |
| Acrotech Biopharma Inc. | 1 | $16 |
| Dilon Technologies, Inc. | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,404 in reported general payments places this provider in the 60th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 31 | $480,251 |
| Lenalidomide | 22 | $306,185 |
| JakafiRuxolitinib Phosphate | 22 | $294,363 |
| TagrissoOsimertinib Mesylate | 12 | $194,397 |
| ErleadaApalutamide | 11 | $157,064 |
| Abiraterone Acetate | 15 | $110,419 |
| EliquisApixaban | 55 | $57,755 |
| XareltoRivaroxaban | 23 | $21,024 |
| Exemestane | 17 | $2,694 |
| Anastrozole | 63 | $990 |
| Letrozole | 54 | $797 |
| Hydroxyurea | 52 | $575 |
| Acyclovir | 33 | $505 |
| Dexamethasone | 52 | $480 |
| Prochlorperazine Maleate | 37 | $468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $162 | $538,00686 claims |
| Incyte CorporationJakafi | $71 | $294,36322 claims |
| AstraZenecaTagrisso | $442 | $194,39712 claims |
| Johnson & JohnsonErleada, Xarelto | $540 | $178,08834 claims |
| Lilly USA, LLCOlanzapine | $56 | $25721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 95 medical oncology providers in Virginia.
Other medical oncology in Leesburg
- David LeeLeesburg$6K
- Janakiraman SubramanianFairfax$562K
- Alexander SpiraFairfax$533K
- Robert DreicerCharlottesville$296K
- Roy BeveridgeFairfax$216K
- Kathleen HarndenFairfax$195K
- Jeanny Aragon-ChingFalls Church$194K
- Nagla Abdel KarimFairfax$131K
- John McCartyRichmond$97K
- Keri MaherRichmond$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.